Interpretation of the FDA Draft Guidance on Pathology Peer Review in Nonclinical Toxicology Studies
Huo Guitao, Qu Zhe, Lin Zhi, Yang Yanwei, Zhang Di, Zhang Hezhan, Lv Jianjun
Chinese Pharmaceutical Affairs ›› 2020, Vol. 34 ›› Issue (2) : 229-235.
Interpretation of the FDA Draft Guidance on Pathology Peer Review in Nonclinical Toxicology Studies
({{custom_author.role_en}}), {{javascript:window.custom_author_en_index++;}}| {{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
| 〈 |
|
〉 |
